Perinorm

Quick links to important sections

Perinorm

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Perinorm

Property Description
Active ingredient Metoclopramide
Form Tablets, Oral solution, Injection
Pharmacological class Anti-emetic agent, Prokinetic agent
General purpose Relieving nausea/vomiting, improving GI motility
Origin Synthetic compound

What Type of Medicine is Perinorm (Metoclopramide)?

Perinorm is a synthetic, single-ingredient pharmaceutical agent containing the active substance Metoclopramide. It is officially classified as a dual-action agent: primarily an Anti-emetic agent used to relieve nausea and vomiting, and secondarily a Prokinetic agent used to promote gastrointestinal (GI) motility. The Metoclopramide molecule is a Benzamide derivative chemically recognized for its unique ability to influence signaling in both the central nervous system and the digestive tract, a property clinically recognized for its therapeutic value.

This distinction is key to its role: unlike certain other anti-nausea medicines that act only centrally, Perinorm achieves its effect by antagonizing specific Dopamine D2 receptors in both the brain's chemoreceptor trigger zone (CTZ) and the GI wall, making it a foundational compound in managing upper gastrointestinal dysfunction.


Perinorm Composition and Available Forms

The core composition relies on the Metoclopramide chemically-defined pure substance. Perinorm is supplied in several Dosage forms to allow for diverse Route of administration. These include Tablets for Oral use, and an Oral solution or Syrup, alongside a Solution for injection for Parenteral administration. The variety in pharmaceutical preparations ensures the medicine can be delivered effectively depending on the required speed of action and patient needs.


General Purpose and Core Benefits of Metoclopramide

The general purpose of Perinorm is to effectively relieve feelings of nausea and stop vomiting by controlling the central reflex. Additionally, its Prokinetic action means it is instrumental in managing conditions related to slow or impaired gastric function. By improving gastric tone and facilitating the movement of material through the stomach and small intestine, the drug offers a benefit that extends beyond simple symptom relief, aiding in the correction of functional digestive issues.

Regulatory References

  1. National Library of Medicine
  2. European Medicines Agency

What side effects are possible with Perinorm?

Possible Side Effects and Safety Information

Perinorm's official safety profile is significantly defined by effects on the Central Nervous System (CNS) and motor control. The regulatory classification identifies drowsiness, fatigue, lassitude, diarrhea, and restlessness (akathisia) as very common or most common adverse reactions.


Serious Adverse Reactions

The most serious documented safety concerns include the risk of Tardive Dyskinesia (TD), a potentially irreversible movement disorder. The risk of TD is explicitly stated to increase with the duration of treatment and total cumulative dose, leading to a regulatory recommendation to avoid use beyond 12 weeks. Other serious reactions include acute Extrapyramidal Symptoms (EPS), typically occurring at the start of treatment, and the rare but severe Neuroleptic Malignant Syndrome (NMS). Serious cardiac events, such as severe bradycardia and cardiac arrest, have been reported, particularly with rapid intravenous administration.


Population-Specific and Endocrine Effects

The safety profile notes distinct considerations for specific groups: pediatric patients have a higher susceptibility to acute EPS, while older adults face an increased risk of TD. The medicine is contraindicated in patients with conditions like gastrointestinal hemorrhage, mechanical obstruction, perforation, or pheochromocytoma. Furthermore, the drug can cause hyperprolactinemia, potentially leading to endocrine-related effects like galactorrhea (breast discharge) and gynecomastia (breast enlargement), as documented in regulatory labeling. The official safety information structures the understanding of risks by detailing these effects and imposing exposure limitations.

Overdose and Emergency Response

Overdose Scope

Property Official Regulatory Information
Documented overdose presentations The documented clinical signs of overexposure include pronounced drowsiness, disorientation, and confusion. Manifestations also include severe extrapyramidal reactions, characterized by unusual, uncontrollable movements.
Physiological systems affected Adverse effects are recorded for the Central Nervous System (CNS) and the Hematologic system, specifically the risk of Methemoglobinemia.
Population-specific overdose notes Unintentional overdose is noted in infants and children using the oral solution. Neonates (premature and full-term) are identified with a risk of developing Methemoglobinemia following overexposure.
When urgent medical help is required Immediate medical attention is mandated by regulators if the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Overdose Response and Management

Property Official Regulatory Information
Antidote or reversal agent Methylene blue is documented for reversing the severe hematologic outcome of Methemoglobinemia; a precaution is noted for patients with G6PD deficiency regarding this specific treatment.
Supportive measures Management is symptomatic and supportive. Anticholinergic or antiparkinson drugs may be administered to control extrapyramidal reactions. The drug is not effectively removed by dialysis procedures.
Duration of effects General overdose symptoms are typically self-limiting, resolving within 24 hours.

Official regulatory documents define the overdose profile by detailing specific clinical manifestations, ranging from CNS effects to severe neurological (seizures) and hematologic complications. The documentation clearly states that immediate emergency medical services must be contacted when critical symptoms, such as collapse or trouble breathing, are observed. Furthermore, the label specifies supportive measures for movement disorders and the necessary antidote for Methemoglobinemia, while noting that general effects typically subside within a 24-hour period.

Therapeutic Uses of Perinorm

What Perinorm Treats: Main Uses and Benefits

Perinorm (Metoclopramide) is commonly used across domains where additional symptomatic support is needed, addressing symptoms related to heightened physiological activity and gastrointestinal stress. It is relevant for easing symptoms associated with both acute emesis and impaired upper GI motility.


Managing Acute and Post-Treatment Nausea and Vomiting

This domain is applied in clinical settings that involve acute or unstable symptom patterns, such as managing postoperative nausea and vomiting (PONV) and pronounced symptoms caused by specific chemotherapy or radiation therapies. The medicine generally helps address symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes by easing distress. The key indications addressed include acute vomiting episodes, symptoms associated with migraine, and emesis resulting from medical interventions. It is commonly used when short-term symptomatic assistance is needed.


Support for Symptoms of Delayed Gastric Emptying and Motility Issues

This use is relevant in conditions characterized by periods of heightened symptoms stemming from delayed gastric emptying (gastroparesis), particularly in diabetic patients. It is used for managing symptoms that interfere with daily comfort, such as uncomfortable abdominal fullness and post-meal bloating. This assists with managing symptoms related to organ-specific functional stress, which contributes to improved comfort during symptomatic periods. It is also applied in addressing chronic symptoms of Gastroesophageal Reflux Disease (GERD).


Quick Fact: Support for Symptoms of Abdominal Fullness

Perinorm is commonly used to help with symptoms related to functional movement stress, which manifests as uncomfortable fullness and bloating after consuming meals.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility Rules for Perinorm (Metoclopramide)

Eligibility for Metoclopramide is strictly defined by regulatory agencies and is based on absolute contraindications and mandatory population restrictions.

Contraindicated Populations and Conditions

Use is strictly prohibited (contraindicated) in several patient groups. This includes individuals with conditions where stimulated gastrointestinal movement could be harmful, suchably Gastrointestinal Hemorrhage, Mechanical Obstruction, or Perforation of the GI tract. The medicine is also contraindicated in patients with specific neurological disorders, such as a history of Tardive Dyskinesia, Epilepsy, Seizure Disorders, or confirmed Parkinson's Disease. Absolute prohibition applies to patients with Pheochromocytoma and infants under one year of age.

Restricted and Conditional Use

Use is restricted across other populations. In pediatric patients (1-18 years), use is limited to short-term, second-line therapy only, with maximum duration restrictions. Patients with moderate to severe renal or hepatic impairment require a mandatory reduction in the administered amount to prevent drug accumulation. For older adults, dose adjustments are often necessary due to increased susceptibility to neurological reactions. Use in lactating mothers is generally not recommended.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Perinorm (Metoclopramide) establishes specific restrictions and monitoring requirements when co-administered with other medicinal products.

Contraindicated and Restricted Combinations

  • Contraindicated Combinations: Co-administration with Levodopa or dopaminergic agonists is prohibited due to the opposing pharmacological actions that result in mutual antagonism.
  • High-Risk Restriction: Use with Monoamine Oxidase Inhibitors (MAOIs) should be avoided due to a documented increased risk of hypertensive reactions.
  • Substance Restriction: Co-administration with alcohol is restricted due to the potentiation of the CNS sedative effects.

Pharmacodynamic and Metabolic Interactions

Metoclopramide is a substrate for the CYP2D6 enzyme. When taken with strong CYP2D6 inhibitors (e.g., specific antidepressants), Metoclopramide’s plasma concentration and systemic exposure are increased, a factor officially documented as raising the risk of extrapyramidal symptoms.

Pharmacodynamic interactions arise when Metoclopramide is combined with other agents that affect the central nervous system. These include neuroleptics, which carry an additive risk of serious movement disorders, and serotonergic drugs, which increase the official risk of Serotonin Syndrome.

Effects on Co-administered Drug Absorption

As a prokinetic agent, Metoclopramide alters gastrointestinal transit time, leading to significant changes in the systemic exposure of certain oral drugs:

  • Cyclosporine Bioavailability: Metoclopramide officially increases the oral absorption and bioavailability of Cyclosporine, which necessitates monitoring of Cyclosporine plasma concentrations.
  • Digoxin Bioavailability: Metoclopramide officially decreases the oral absorption of Digoxin, requiring monitoring of Digoxin plasma concentrations.

Population-Specific Notes

In patients with renal impairment (creatinine clearance < 60 mL/min), Metoclopramide clearance is reduced. This reduction leads to drug accumulation, a condition that may exacerbate the risk of drug interaction-related adverse effects.

Mechanism of Action

How Perinorm Works: Pharmacodynamic Mechanism

Perinorm's mechanism involves a dual interaction across the central and peripheral nervous systems. Centrally, the molecule acts as an antagonist on Dopamine mathbfD2 receptors located within the Chemoreceptor Trigger Zone (CTZ) of the brainstem. This blockade inhibits the D2-mediated signaling pathway that activates the brain's vomiting center, leading to the inhibition of the emetic reflex arc.

Peripherally, the drug functions as an agonist on Serotonin mathbf5-HT4 receptors in the enteric nervous system. This 5-HT4 activation facilitates the release of Acetylcholine (ACh), resulting in enhanced tone of the Lower Esophageal Sphincter and modulation of smooth muscle contractions (peristalsis) in the stomach and duodenum. This combination of central D2 antagonism and peripheral 5-HT4 agonism provides a coordinated dual mechanism that modulates both the central reflex arc and the peripheral motor function of the digestive tract. The primary prokinetic effect is limited to the upper GI tract, and the D2 antagonism can, at higher concentrations, extend to motor pathways in the brain.

Dosage and Administration Information

Administration Overview

Perinorm is typically administered in a clinical or home setting based on the specific needs of the individual. The method of administration depends on the formulation prescribed, which can include oral tablets, liquid syrups, or injectable solutions.

Oral Formulations

When taking oral forms of this medication, it is generally recommended to take the dose at a consistent time each day. This is often done before meals to ensure optimal absorption and effectiveness in managing gastrointestinal symptoms.

Injectable Formulations

Injectable versions are administered by healthcare professionals via intramuscular or intravenous routes. This method is usually reserved for acute situations or when oral intake is not feasible.

General Considerations for Use

To achieve the intended outcome, the following practices are standard:

  • Consistency: Maintaining a regular schedule helps keep a steady level of the medication in the system.
  • Duration: The length of use is determined by the specific condition being addressed and the individual's response to the initial doses.
  • Formulation Specifics: Liquid forms should be measured with a standardized device to ensure the correct amount is taken.

Monitoring and Adjustments

Usage is typically monitored over a short-term period. If symptoms persist or if the individual experiences changes in their condition, the approach to use may be reassessed. It is common for the frequency of use to be adjusted based on the timing of symptoms, such as before specific triggers or events that cause discomfort.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Perinorm (Metoclopramide)


Research Evidence for Managing Diabetic Gastroparesis Symptoms

Short-term Randomized Controlled Trials (RCTs) and systematic reviews have explored Metoclopramide in this area. These studies were used in research exploring symptom patterns and their evaluation for adults diagnosed with diabetic gastroparesis. Researchers examined overall patient-reported outcomes describing perceived discomfort, as well as objective measures like the rate at which the stomach emptied. Studies reported patterns observed in the studies related to the evaluation of overall symptom scores during the trial periods. However, these research findings were primarily derived from short study periods, typically lasting only a few weeks. What remains uncertain is the durability of reported changes, as there is limited information for long-term outcomes.


Research Evidence for Acute Nausea and Vomiting

Research has explored Metoclopramide in conditions associated with acute or disruptive episodes, such as following surgery (PONV) or chemotherapy (CINV).

For Postoperative Nausea and Vomiting (PONV), the research base evaluating Metoclopramide in the setting of post-surgical nausea and vomiting is drawn from very short-term RCTs and meta-analyses. Studies monitored the incidence of nausea and vomiting. Research describes data patterns observed regarding the measured occurrence of PONV. However, comparative evidence is lacking when assessing its performance against contemporary anti-emetic agents.

For Chemotherapy-Induced Nausea and Vomiting (CINV), Metoclopramide was evaluated in studies focusing on episodes where symptoms become more noticeable, such as delayed CINV. Studies observed patterns related to symptom evolution when high doses were administered, and findings indicate these results reflect the specific conditions under which they were conducted. Research highlights that standard doses led to findings that demonstrated greater variability.


Main Evidence Gaps and Areas of Uncertainty

The evidence base contains several key limitations. Follow-up durations were limited across many core studies, leading to uncertainty regarding long-term outcomes. Furthermore, certain groups, such as those with specific comorbidities or the pediatric population, lack dedicated study. Regulatory agencies have noted that the evidence is limited and inconsistent for chronic uses, such as long-term management of GERD. Data for these specific conditions remain insufficient to draw broad conclusions.

Key Studies & References

  1. U.S. National Library of Medicine (NLM): Metoclopramide Drug Information

Frequently Asked Questions (FAQ)

Common questions about Perinorm (FAQ)


Q: What is the main difference between Perinorm and other similar medicines?

Perinorm (metoclopramide) is officially classified as having a dual action. It works centrally in the brain as an Anti-emetic to help relieve feelings of nausea and stop vomiting. It also works peripherally as a Prokinetic agent to help promote the movement of food through the upper digestive tract. This combination of effects on both the central reflex and peripheral movement is what distinguishes it from many other anti-nausea medicines.


Q: How long does it usually take for Perinorm to start working?

According to official product information, the time it takes for the medicine to start working depends on the way it is given. Following an oral dose (tablet or solution), official information indicates that effects typically begin within 30 to 60 minutes. If administered by injection, the onset of action is much quicker.


Q: How long does the effect of Perinorm last after use?

Factual information indicates that the therapeutic effects of the medicine typically persist for 1 to 2 hours following administration. The average elimination half-life of the drug in people with normal kidney function is noted to be approximately 5 to 6 hours.


Q: Is Perinorm an over-the-counter medicine or is a prescription required?

Perinorm (metoclopramide) is categorized as a prescription-only medicine in most regulatory regions. This means it is generally not available for purchase without a prescription from a licensed healthcare professional.


Q: Can Perinorm be used for headache relief?

Official documentation does not list the medicine as indicated for the relief of general headache pain. Regulatory documents do, however, mention its use for the symptomatic treatment of nausea and vomiting when associated with an acute migraine, based on official regulatory approvals in some regions.


Q: What should I do if I miss a use of Perinorm?

Official patient instructions often advise that if a specific use is missed, the recommended procedure is to skip that missed amount and take the next amount at the regularly scheduled time. They advise against taking a double amount to try to make up for the forgotten one.


Q: Can I stop using Perinorm suddenly?

Official patient information notes that if the medicine is abruptly stopped, especially following long-term or high-dose use, patients may experience withdrawal symptoms. These symptoms can include feelings of nervousness, dizziness, or headache. Regulatory warnings indicate that a gradual reduction in the amount used may be necessary to help prevent these effects.


Q: Does Perinorm cause weight gain?

Weight gain is not listed as a common, very common, or serious adverse reaction in the official regulatory safety profile for this medicine. The profile emphasizes potential Central Nervous System (CNS) effects like drowsiness and movement disorders.


Q: Are there any specific foods or drinks to avoid while using Perinorm?

Official restrictions primarily focus on alcohol, which should be avoided due to the documented potential to increase the sedative effects on the central nervous system. General food consumption is not restricted, and the oral form is advised to be taken before meals for certain indications.


Q: Can Perinorm be used to prevent travel-related sickness?

The approved indications for Perinorm focus on relieving or preventing acute nausea and vomiting related to conditions like surgery, chemotherapy, or impaired gastric function. Official regulatory documents do not include travel-related sickness as an approved indication for this medicine.


Q: Why is Perinorm sometimes described as helping with migraine symptoms?

European regulatory documents (SmPC) and other international bodies list the medicine as indicated for the symptomatic treatment of nausea and vomiting associated with acute migraine. Its primary role in this context is to address the severe stomach upset often accompanying a migraine attack.


Q: Can Perinorm be used for persistent hiccups?

While the medicine has effects on the digestive and nervous systems, the approved indications in major regulatory markets focus on nausea, vomiting, and specific GI motility disorders. Official regulatory labeling does not include persistent hiccups as an approved use.


Q: Why are there different strengths of Perinorm available?

Regulatory documents indicate that different strengths are available to support flexible administration based on clinical need. The medicine often requires dose adjustments for certain patient groups, such as older adults or those with renal (kidney) or hepatic (liver) impairment, and different strengths help facilitate this.


Q: Does Perinorm interact with supplements like vitamins or herbal products?

Authoritative patient information generally mentions the importance of discussing all medicines, including vitamins, supplements, and herbal remedies, with a healthcare professional. This is because there is often insufficient information available to confirm that complementary medicines are safe to take with Perinorm.


Q: Does Perinorm interact with diabetes medications?

Official labeling specifically notes a precaution for patients with diabetes. It is stated that the dose of insulin may need to be adjusted if a patient uses this medicine. This is likely due to the medicine's effect on how quickly the stomach empties, which can change the timing of nutrient absorption.


Q: Is Perinorm addictive or habit-forming?

Official warnings focus on the risk of serious, potentially irreversible movement disorders, such as Tardive Dyskinesia, with extended use. Regulatory documents do not classify the medicine as a controlled substance or explicitly describe it as 'addictive' or 'habit-forming,' but they do advise on potential withdrawal symptoms if use is stopped suddenly.


Q: What should I do if I experience a rare side effect mentioned in the leaflet?

Patient safety guidance advises that if a rare or serious side effect is experienced, seeking medical assistance is generally recommended. It is also advised to report the event to the relevant national drug safety agency for regulatory oversight.


Q: Can Perinorm be used for symptoms other than the primary stated uses?

Regulatory documents define a specific set of approved or indicated uses for the medicine, such as relieving nausea/vomiting and treating gastric motility issues. The official product labeling does not include information regarding use outside of these designated conditions.


Q: Is a metallic taste in the mouth an expected experience with Perinorm?

A metallic taste is not listed among the most common adverse reactions in the official safety profile. It may be mentioned in extended lists of side effects where the frequency is noted as 'not known' or 'rare', meaning its clear link to the medicine has not been officially established as a common experience.


Q: Can Perinorm be crushed or mixed with food?

Official instructions for the tablet form often advise swallowing the tablets whole. However, the medicine is also available as an oral solution, and some patient guidance notes that the tablets may be taken with or without food.


Q: Why is Perinorm restricted in some countries or for certain uses?

Regulatory agencies, particularly in North America and Europe, have placed restrictions on the medicine primarily to minimize the risk of neurological adverse reactions. This includes the potentially irreversible movement disorder known as Tardive Dyskinesia. These restrictions often limit the maximum dose and the duration of time the medicine can be used.


Q: Is Perinorm a common medicine, or is it reserved for specific conditions?

The medicine is generally reserved for short-term use and specific conditions, such as short-term nausea or specific gastric motility problems. For example, in the US, it is indicated for conditions only after other treatments have not worked, highlighting its reserved role in therapy.


Q: Is there a specific time of day that Perinorm is typically used?

Official administration instructions specify that the oral dose is typically taken 30 minutes before each meal and at bedtime for certain long-term indications. Therefore, the use is often spread throughout the day rather than being confined to one single time.


Q: Are generic versions of Perinorm available?

Yes, regulatory databases confirm that generic versions of metoclopramide, the active ingredient in Perinorm, are approved and available. This means that versions of the medicine marketed under the non-brand name are often available.


Q: Are there different brand names that contain the same medicine as Perinorm?

Yes, the active ingredient, metoclapromide, is available under multiple brand names globally. Examples include Reglan (commonly used in the US) and Maxolon.

How should Perinorm be stored and disposed of?

Official Storage and Disposal Requirements

Perinorm (Metoclopramide) storage and disposal must adhere to specific regulatory requirements to ensure product integrity and environmental safety.

Storage Conditions:

Requirement Details
Temperature Store the product between 15 °C and 30 °C.
Light Protection The medicine must be protected from light to maintain its stability.
Handling Do not freeze the product. Discard any unused portion of the single-dose injection vial immediately after use.

Disposal Rules:

Expired or unused Perinorm must not be placed in household trash or poured down drains, as this can lead to environmental contamination. Disposal must be completed through an approved pharmaceutical waste process, following local and national regulations for medical waste. This ensures proper handling of sharps and unused medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Perinorm found in:

A-Z Index: